Zipp Mobility, the Irish dockless e-scooter start-up, has closed a €300,000 seed investment round and expanded its team to target the UK e-scooter market. 

The seed funding round was led by a London-based VC and private angel investors.

Zipp Mobility, founded by Charlie Gleeson last year, is headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin (UCD).

The company positions itself as a solution to the "last mile" problem, acting as the link between public transport stops and a commuter's final destination. 

Last month, the UK government announced plans to accelerate city trials of rented e-scooter schemes to any region of the country that wants to operate these schemes in partnership with scooter firms. 

Such trials were originally planned for June 2021 and only in four local authority regions; Portsmouth and Southampton, the West of England Combined Authority, Derby and Nottingham, and the West Midlands. 

But now all UK regions are permitted to launch e-scooter sharing schemes in their cities, as part of the UK government's plans to explore less congested and greener methods of urban transport in response to Covid-19.

Charlie Gleeson said the start-up had originally planned to trial its e-scooters with students on Irish university campuses, including UCD, earlier this year, but then Covid-19 arrived. 

"Following on from the recent announcement by the UK government to bring forward and expand their e-scooter trials country-wide, we have now pivoted to focus on the UK market," he said.

Mr Gleeson said that while the company's current focus is on the UK market, Irish university campuses are particularly attractive locations in which Zipp Mobility can build a strong customer base.

"Tapping into such a concentrated pool of young people is fertile ground for proving e-scooter demand on a wider scale. It will also serve as a medium of convincing Irish government bodies of the viability and safety of the service. Plans to trial on campuses are currently in development," he added.